comparemela.com
Home
Live Updates
Mirvetuximab soravtansine shows antitumor activity in platinum resistant ovarian cancer : comparemela.com
Mirvetuximab soravtansine shows antitumor activity in platinum resistant ovarian cancer
Mirvetuximab soravtansine demonstrated efficacy and tolerability in patients with platinum resistant ovarian cancer, according to phase 3 clinical data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Related Keywords
Phoenix
,
Arizona
,
United States
,
Ursula Matulonis
,
Ovarian Cancer Research Alliance
,
Rivkin Foundation
,
Alkermes
,
Harvard Medical School
,
Novartis
,
Astrazeneca
,
Clearity Foundation
,
Dana Farber Cancer Institute
,
Gynecologic Oncology Annual Meeting
,
Blueprint Medicines
,
Brock Wilson Family Chair
,
Harvard Medical
,
Published March
,
comparemela.com © 2020. All Rights Reserved.